Differential and epigenetic gene expression profiling identifies frequent disruption of the RELN pathway in pancreatic cancers.

BACKGROUND & AIMS Recently described genome-wide approaches robustly detect many candidate genes that are regulated by DNA methylation, but many of these genes do not represent important targets for functional inactivation. Here we used a microarray-based strategy to identify biologically relevant genes associated with epigenetic silencing in pancreatic cancer. METHODS We compared information from differential gene expression analysis with the transcriptional responses to epigenetic modifiers. RESULTS Using this approach, we identified 7 novel targets for aberrant methylation in pancreatic cancer. One of the genes identified, RELN (Reelin), a key regulator of neuronal migration, is frequently silenced in pancreatic cancers, as are several of its downstream mediators. Importantly, small interfering RNA-mediated knockdown of RELN in pancreatic cancer cells that retain RELN expression resulted in greatly enhanced cell motility, invasiveness, and colony-forming ability. Increased cell motility was also induced by knockdown of downstream components of the RELN pathway, including ApoER2, VLDLR, and DAB1. Treatment of pancreatic cancer cells with histone deacetylase inhibitors, valproic acid and suberoylanilide hydroxamic acid, restored the expression of RELN and DAB1 and markedly inhibited their migration. CONCLUSIONS The high prevalence of the silencing of RELN pathway components and its reversal by histone deacetylase inhibitors suggest the importance of this pathway as a diagnostic and therapeutic target for pancreatic cancer.

[1]  A. Guidotti,et al.  DNA methyltransferase 1 regulates reelin mRNA expression in mouse primary cortical cultures. , 2005, Proceedings of the National Academy of Sciences of the United States of America.

[2]  U. Germing,et al.  Treatment of myelodysplastic syndromes with valproic acid alone or in combination with all-trans retinoic acid. , 2004, Blood.

[3]  C. Iacobuzio-Donahue,et al.  Frequent hypomethylation of multiple genes overexpressed in pancreatic ductal adenocarcinoma. , 2003, Cancer research.

[4]  S. Minucci,et al.  Methyltransferase Recruitment and DNA Hypermethylation of Target Promoters by an Oncogenic Transcription Factor , 2002, Science.

[5]  S. Faraone,et al.  Hypermethylation of the reelin (RELN) promoter in the brain of schizophrenic patients: A preliminary report , 2005, American journal of medical genetics. Part B, Neuropsychiatric genetics : the official publication of the International Society of Psychiatric Genetics.

[6]  J. Cameron,et al.  The SMAD4 protein and prognosis of pancreatic ductal adenocarcinoma. , 2001, Clinical cancer research : an official journal of the American Association for Cancer Research.

[7]  A. Guidotti,et al.  DNA-methyltransferase 1 mRNA is selectively overexpressed in telencephalic GABAergic interneurons of schizophrenia brains , 2003, Proceedings of the National Academy of Sciences of the United States of America.

[8]  P. Laird.  Early detection: The power and the promise of DNA methylation markers , 2003, Nature Reviews Cancer.

[9]  R H Hruban,et al.  Hypermethylation of multiple genes in pancreatic adenocarcinoma. , 2000, Cancer research.

[10]  M. Paz,et al.  Genetic unmasking of epigenetically silenced tumor suppressor genes in colon cancer cells deficient in DNA methyltransferases. , 2003, Human molecular genetics.

[11]  M. Tsao,et al.  Long-term culture and immortalization of epithelial cells from normal adult human pancreatic ducts transfected by the E6E7 gene of human papilloma virus 16. , 1996, The American journal of pathology.

[12]  T. Yeatman,et al.  Clusterin-Mediated Apoptosis Is Regulated by Adenomatous Polyposis Coli and Is p21 Dependent but p53 Independent , 2004, Cancer Research.

[13]  M. Goggins,et al.  Epigenetic Down-Regulation of CDKN1C/p57KIP2 in Pancreatic Ductal Neoplasms Identified by Gene Expression Profiling , 2005, Clinical Cancer Research.

[14]  Joachim Herz,et al.  Direct Binding of Reelin to VLDL Receptor and ApoE Receptor 2 Induces Tyrosine Phosphorylation of Disabled-1 and Modulates Tau Phosphorylation , 1999, Neuron.

[15]  M. Toyota,et al.  Inactivation of p57KIP2 by regional promoter hypermethylation and histone deacetylation in human tumors , 2002, Oncogene.

[16]  A. Guidotti,et al.  Reelin promoter hypermethylation in schizophrenia. , 2005, Proceedings of the National Academy of Sciences of the United States of America.

[17]  H. Bock,et al.  Reelin-mediated Signaling Locally Regulates Protein Kinase B/Akt and Glycogen Synthase Kinase 3β* , 2002, The Journal of Biological Chemistry.

[18]  J. Cameron,et al.  Gene expression profiling identifies genes associated with invasive intraductal papillary mucinous neoplasms of the pancreas. , 2004, The American journal of pathology.

[19]  R. Hruban,et al.  SPARC/osteonectin is a frequent target for aberrant methylation in pancreatic adenocarcinoma and a mediator of tumor–stromal interactions , 2003, Oncogene.

[20]  T. Curran,et al.  Role of the reelin signaling pathway in central nervous system development. , 2001, Annual review of neuroscience.

[21]  F. Sato,et al.  Pharmacologic unmasking of epigenetically silenced tumor suppressor genes in esophageal squamous cell carcinoma. , 2002, Cancer cell.

[22]  John Shelton,et al.  Reeler/Disabled-like Disruption of Neuronal Migration in Knockout Mice Lacking the VLDL Receptor and ApoE Receptor 2 , 1999, Cell.

[23]  Y. Yarden,et al.  Csk Homologous Kinase, a Novel Signaling Molecule, Directly Associates with the Activated ErbB-2 Receptor in Breast Cancer Cells and Inhibits Their Proliferation* , 1998, The Journal of Biological Chemistry.

[24]  Ping Zhu,et al.  Valproic acid defines a novel class of HDAC inhibitors inducing differentiation of transformed cells , 2001, The EMBO journal.

[25]  Victor X Jin,et al.  Loss of Estrogen Receptor Signaling Triggers Epigenetic Silencing of Downstream Targets in Breast Cancer , 2004, Cancer Research.

[26]  P. Marks,et al.  Structures of a histone deacetylase homologue bound to the TSA and SAHA inhibitors , 1999, Nature.

[27]  M. Goggins.  Molecular markers of early pancreatic cancer. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[28]  P. Marks,et al.  Histone deacetylase inhibitors: from target to clinical trials , 2002, Expert opinion on investigational drugs.

[29]  J. Cameron,et al.  Discovery of novel targets for aberrant methylation in pancreatic carcinoma using high-throughput microarrays. , 2003, Cancer research.

[30]  S. Clark,et al.  Hypermethylation trigger of the glutathione-S-transferase gene (GSTP1) in prostate cancer cells , 2002, Oncogene.

[31]  Jonathan A. Cooper,et al.  Reelin-induced tryosine phosphorylation of Disabled 1 during neuronal positioning , 1999 .

[32]  D. Grayson,et al.  Histone deacetylase inhibitors decrease reelin promoter methylation in vitro , 2005, Journal of neurochemistry.

[33]  J. Herman,et al.  GATA-4 and GATA-5 Transcription Factor Genes and Potential Downstream Antitumor Target Genes Are Epigenetically Silenced in Colorectal and Gastric Cancer , 2003, Molecular and Cellular Biology.

[34]  R. Blaheta,et al.  Evolving anticancer drug valproic acid: Insights into the mechanism and clinical studies , 2005, Medicinal research reviews (Print).

[35]  T. Curran,et al.  A protein related to extracellular matrix proteins deleted in the mouse mutant reeler , 1995, Nature.

[36]  A. Guidotti,et al.  An epigenetic mouse model for molecular and behavioral neuropathologies related to schizophrenia vulnerability , 2002, Proceedings of the National Academy of Sciences of the United States of America.

[37]  A. Goffinet,et al.  Reelin and brain development , 2003, Nature Reviews Neuroscience.

[38]  Peter A. Jones,et al.  The fundamental role of epigenetic events in cancer , 2002, Nature Reviews Genetics.

[39]  Matty P. Weijenberg,et al.  A genomic screen for genes upregulated by demethylation and histone deacetylase inhibition in human colorectal cancer , 2002, Nature Genetics.

[40]  S. Fatemi,et al.  Reelin glycoprotein: structure, biology and roles in health and disease , 2005, Molecular Psychiatry.

[41]  Y. Miyagi,et al.  Epigenetic inactivation of TFPI-2 as a common mechanism associated with growth and invasion of pancreatic ductal adenocarcinoma , 2005, Oncogene.

[42]  Ying Chen,et al.  On the epigenetic regulation of the human reelin promoter , 2002, Nucleic Acids Res..

[43]  R. Hruban,et al.  Identification and characterization of differentially methylated CpG islands in pancreatic carcinoma. , 2001, Cancer research.

[44]  Peter A. Jones,et al.  Epigenetics in human disease and prospects for epigenetic therapy , 2004, Nature.

[45]  R. Hruban,et al.  Characterization of gene expression in mucinous cystic neoplasms of the pancreas using oligonucleotide microarrays , 2004, Oncogene.

[46]  Wei Dong Chen,et al.  Epigenetic inactivation of SFRP genes allows constitutive WNT signaling in colorectal cancer , 2004, Nature Genetics.

[47]  Jonathan A. Cooper,et al.  Neuronal position in the developing brain is regulated by mouse disabled-1 , 1997, Nature.

[48]  L. Schwartz,et al.  Phase I clinical trial of histone deacetylase inhibitor: suberoylanilide hydroxamic acid administered intravenously. , 2003, Clinical cancer research : an official journal of the American Association for Cancer Research.

[49]  J. Herman,et al.  Gene silencing in cancer in association with promoter hypermethylation. , 2003, The New England journal of medicine.

[50]  M. Sheng,et al.  Nuclear translocation and transcription regulation by the membrane-associated guanylate kinase CASK/LIN-2 , 2000, Nature.